(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/093663 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/04* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/CN2022/133171

(22) International Filing Date:
21 November 2022 (21.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202111404293.6 24 November 2021 (24.11.2021) CN

(71) Applicant: **SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.** [CN/CN]; No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai 201318 (CN).

(72) Inventors: **LUO, Huibing**; No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai 201318 (CN). **LI, Qing**; No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai 201318 (CN).

(74) Agent: **CHINA PATENT AGENT (H.K.) LTD.**; 22/F., Great Eagle Centre, 23 Harbour Road, Wanchai, Hong Kong (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/093663 A1

(54) Title: PHARMACEUTICAL COMPOSITION AND USE THEREOF

(57) Abstract: The present disclosure provides a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib or a pharmaceutically acceptable salt thereof, or said pharmaceutical composition in manufacture of a medicament for treating and/or preventing a disease mediated by HER2 exon 20 insertion mutation and/or EGFR rare mutation. The pharmaceutical composition of the present disclosure shows an excellent therapeutic effect on disease mediated by HER2 exon 20 insertion mutation and/or EGFR rare mutation (for example, non-small cell lung cancer (NSCLC)) with little side effects and excellent safety.